# Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia

> **NCT00809042** · PHASE2 · COMPLETED · sponsor: **Shiraz University of Medical Sciences** · enrollment: 120 (estimated)

## Conditions studied

- β-Thalassemia Intermedia

## Interventions

- **DRUG:** hydroxyurea
- **DRUG:** L-carnitine and hydroxyurea
- **DRUG:** hydroxyurea and magnesium chloride
- **DRUG:** hydroxyurea,L-carnitine and magnesium chloride

## Key facts

- **NCT ID:** NCT00809042
- **Lead sponsor:** Shiraz University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-11
- **Final completion:** 2007-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2008-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00809042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00809042, "Combination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermedia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00809042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*